Reversible Secondary Adrenal Insufficiency Associated with Tucatinib Therapy in a Patient with HER2-Positive Breast Cancer
SUMMARY: Tucatinib is a highly selective, oral, reversible human epidermal growth factor receptor 2 (HER2)-specific tyrosine kinase inhibitor approved for the treatment of metastatic HER2-positive breast cancer. While its established adverse effects include diarrhoea, hepatotoxicity, and palmar-plantar erythrodysesthesia, endocrine toxicities have not been described in the Summary of Product Characteristics (SPC) or published literature. We report a case of secondary adrenal insufficiency in a 73-year-old woman receiving Tucatinib in combination with Trastuzumab and Capecitabine. She developed worsening hyponatremia and biochemical evidence of central adrenal suppression without prior steroid or opioid exposure. Sodium normalized promptly with glucocorticoid replacement. Following discontinuation of Tucatinib, hypothalamic-pituitary-adrenal (HPA) axis function recovered, and steroid therapy was successfully withdrawn. This case highlights a previously unreported potential endocrine adverse effect of Tucatinib and underscores the importance of vigilance for adrenal dysfunction in patients receiving targeted therapies.
Authors
- M. Parton
- Daniel L. Morganstein (ORCID: https://orcid.org/0000-0003-1565-8617)
- Imane Boughazi (ORCID: https://orcid.org/0000-0002-3187-6393)
- Chloe Chan
Institutions
- Royal Marsden Hospital (GB)
- Chelsea and Westminster Hospital (GB)
Publication Details
- Journal
- Endocrine Oncology
- Published
- 2026-11-20
- DOI
- https://doi.org/10.1530/eo-26-0050
- Primary Topic
- Adrenal Hormones and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00